Tefinostat

DB15321InvestigationalSmall molecule

Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).

Mechanism: Pharmacologically active on Histone deacetylase
Curator reviewed
Formula / weight: C₂₈H₃₇N₃O₅ · 495.62 g/mol (avg)

Resolves to

Compound

UNIIZAU91150SBCAS914382-60-8

Structure

InChIKeyGLNWREBYRLDPQP-MHZLTWQESA-NSMILESONC(=O)CCCCCCC(=O)NC1=CC=C(CN[C@H](C(=O)OC2CCCC2)C2=CC=CC=C2)C=C1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

40Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Tefinostat, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account